New York Life Investment Management LLC Increases Holdings in Solventum Corporation $SOLV

New York Life Investment Management LLC increased its position in Solventum Corporation (NYSE:SOLV) by 64.0% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 32,746 shares of the company’s stock after buying an additional 12,773 shares during the quarter. New York Life Investment Management LLC’s holdings in Solventum were worth $2,595,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Hilltop National Bank grew its position in Solventum by 71.3% during the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after acquiring an additional 129 shares during the last quarter. Measured Wealth Private Client Group LLC bought a new stake in shares of Solventum in the 3rd quarter worth approximately $25,000. Deseret Mutual Benefit Administrators lifted its holdings in shares of Solventum by 78.7% in the 3rd quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock worth $27,000 after acquiring an additional 163 shares during the last quarter. JNBA Financial Advisors boosted its stake in shares of Solventum by 205.4% in the 4th quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock valued at $27,000 after purchasing an additional 228 shares in the last quarter. Finally, CYBER HORNET ETFs LLC bought a new position in shares of Solventum during the 2nd quarter valued at $28,000.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on SOLV. Stifel Nicolaus decreased their target price on shares of Solventum from $105.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. UBS Group cut Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a research note on Thursday, May 14th. Wedbush started coverage on Solventum in a report on Friday. They issued an “outperform” rating and a $94.00 price objective on the stock. Piper Sandler lowered their target price on Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Solventum in a report on Tuesday, January 27th. Eight research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $84.25.

Insider Transactions at Solventum

In other Solventum news, Director Amy Mcbride Wendell purchased 1,475 shares of Solventum stock in a transaction that occurred on Tuesday, March 10th. The shares were bought at an average price of $68.03 per share, for a total transaction of $100,344.25. Following the acquisition, the director directly owned 5,039 shares in the company, valued at approximately $342,803.17. This trade represents a 41.39% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.24% of the stock is currently owned by corporate insiders.

Solventum Trading Up 2.5%

Shares of SOLV opened at $76.14 on Tuesday. The stock has a market capitalization of $13.19 billion, a P/E ratio of 9.33, a PEG ratio of 1.15 and a beta of 0.59. Solventum Corporation has a twelve month low of $62.38 and a twelve month high of $88.20. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96. The firm has a fifty day simple moving average of $68.05 and a two-hundred day simple moving average of $74.62.

Solventum (NYSE:SOLV) last released its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.35 by $0.13. The firm had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The company’s revenue for the quarter was down 3.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.34 earnings per share. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, research analysts anticipate that Solventum Corporation will post 6.58 EPS for the current year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.